Under Secretary Azar and Administrator Verma’s stewardship, HHS and CMS have pursued an ambitious policy agenda on transparency, drug pricing, and medical device reimbursement, one the Biden Administration is unlikely to abandon.
HHS Regulations With Enduring Impact On Pricing And Reimbursement Of Medical Services And Technologies
